Drug Approval | October 31, 2025
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
